earnings
confidence high
sentiment positive
materiality 0.80
BioCryst Q1 ORLADEYO revenue $134.2M (+51% YoY); raises FY guidance to $580-600M; expects FY 2025 profitability
BIOCRYST PHARMACEUTICALS INC
2025-Q1 EPS reported
$0.00
revenue$145,534,000
- Q1 ORLADEYO net rev $134.2M (+51% YoY); total rev $145.5M (+56.8% YoY); net income $32K vs loss $35.4M.
- FY 2025 ORLADEYO rev guidance raised to $580-600M (from $535-550M); company expects net income and positive cash flow for full year.
- Paid down $75M of Pharmakon debt in April; expects ~$23.5M interest savings over life of loan.
- NDA submitted for ORLADEYO oral granules for HAE children aged 2-11; IND cleared for BCX17725 for Netherton syndrome.
- % paid ORLADEYO patients increased to ~84% (from 73.5% end 2024); U.S. preference for oral prophylaxis rose to 70%.